Intraperitoneal administration of thermosensitive hydrogel Co-loaded with norcantharidin nanoparticles and oxaliplatin inhibits malignant ascites of hepatocellular carcinoma

Susu Xiao, Yu Wang, Wenqiong Ma, Ping Zhou, Biqiong Wang, Zhouxue Wu, Qian Wen, Kang Xiong, Yanlin Liu & Shaozhi Fu
Malignant ascites is a common complication of some advanced cancers. Although intraperitoneal (IP) administration of chemotherapy drugs is routinely used to treat cancerous ascites, conventional drugs have poor retention and therefore need to be administered frequently to maintain a sustained anti-tumor effect. In this study, a thermosensitive hydrogel composite loaded with norethindrone nanoparticles (NPs) and oxaliplatin (N/O/Hydrogel) was developed to inhibit ascites of hepatocellular carcinoma (HCC) through IP injection. N/O/Hydrogel induced apoptosis in the H22...
1 citation reported since publication in 2022.
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.